1.Time to Take Sleeping Pills and Subjective Satisfaction among Cancer Patients
Soyoung YOUN ; Byeongil CHOI ; Suyeon LEE ; Changnam KIM ; Seockhoon CHUNG
Psychiatry Investigation 2020;17(3):249-255
Objective:
We investigated the influence of the time to take hypnotics and daytime activity on patient satisfaction with sleeping pills.
Methods:
Ninety-six cancer patients who were currently taking benzodiazepine or z-drug as hypnotics were grouped into satisfied and dissatisfied groups. The subjects’ symptoms, time to take sleeping pills, bedtime, sleep onset time, wake up time, and time in bed within 24 hours (TIB/d) were obtained.
Results:
The satisfied group had significantly late sleeping pill ingestion time (p=0.04); significantly early wake up time (p=0.01); and significantly shorter sleep latency, TIB/d, duration from the administration of pills to sleep onset, and duration from the administration of pills to wake up time (PTW). Logistic regression analysis revealed that the significant predictors of patient satisfaction to hypnotics were less severity of insomnia [odds ratio (OR)=0.91] and the time variables, including late sleeping pill administration time (OR=1.53) and early wake up time (OR=0.57). Among the duration variables, short PTW (OR=0.30) and short TIB/d (OR=0.64) were significantly related with the satisfaction to hypnotics.
Conclusion
Reducing the duration from the administration of hypnotics to wake up time and TIB/d can influence the satisfaction to sleeping pills.
2.Psychological Distress and Drawing Tests among Women with Breast Cancer.
Jiyeon KIM ; Soyoung YOUN ; Byeongil CHOI ; Kyung Hae JUNG ; Seung Do AHN ; Sook Yeon HWANG ; Seockhoon CHUNG ; Jaedam LEE
Journal of Korean Medical Science 2018;33(17):e140-
BACKGROUND: The aim of this study was to evaluate the use of the Diagnostic Drawing Series (DDS) as a screening tool for the breast cancer patients with psychological distress. METHODS: All of 64 patients with breast cancer participated in this study. Patients' depressive and anxiety symptoms were assessed using Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) when the DDS was applied to the partipicants. RESULTS: Depressed patients used more enclosure in the Feeling drawings (P = 0.002) and tilt in Free drawings (P = 0.048). Patients with anxiety drew a picture over 67% of the paper (P = 0.015) in Tree drawing and more medium pressure (P = 0.049) in Feeling drawings. Thirty four subjects (77.3%) of unstable emotion group used over 67% of the space (P = 0.002). More Landscapes were observed in the Feeling drawings of unstable patients (P = 0.042). CONCLUSION: These results suggested that DDS could be used as a supplemental screening tool for psychological distress in breast cancer patients.
Anxiety
;
Breast Neoplasms*
;
Breast*
;
Depression
;
Female
;
Humans
;
Mass Screening
;
Trees
3.Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma.
Ho Shin GWAK ; Gi Taek YEE ; Chul Kee PARK ; Jin Wook KIM ; Yong Kil HONG ; Seok Gu KANG ; Jeong Hoon KIM ; Ho Jun SEOL ; Tae Young JUNG ; Jong Hee CHANG ; Heon YOO ; Jeong Hyun HWANG ; Se Hyuk KIM ; Bong Jin PARK ; Sun Chul HWANG ; Min Su KIM ; Seon Hwan KIM ; Eun Young KIM ; Ealmaan KIM ; Hae Yu KIM ; Young Cho KO ; Hwan Jung YUN ; Ji Hye YOUN ; Juyoung KIM ; Byeongil LEE ; Seung Hoon LEE
Journal of Korean Neurosurgical Society 2013;54(6):489-495
OBJECTIVE: To evaluate the efficacy of temozolomide (TMZ) chemotherapy for recurrent anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA). METHODS: A multi-center retrospective trial enrolled seventy-two patients with histologically proven AO/AOA who underwent TMZ chemotherapy for their recurrent tumors from 2006 to 2010. TMZ was administered orally (150 to 200 mg/m2/day) for 5 days per 28 days until unacceptable toxicity occurred or tumor progression was observed. RESULTS: TMZ chemotherapy cycles administered was median 5.3 (range, 1-41). The objective response rate was 24% including 8 cases (11%) of complete response and another 23 patients (32%) were remained as stable disease. Severe side effects (> or =grade 3) occurred only in 9 patients (13%). Progression-free survival (PFS) of all patients was a median 8.0 months (95% confidence interval, 6.0-10.0). The time to recurrence of a year or after was a favorable prognostic factor for PFS (p<0.05). Overall survival (OS) was apparently differed by the patient's histology, as AOA patients survived a median OS of 18.0 months while AO patients did not reach median OS at median follow-up of 11.5 months (range 2.7-65 months). Good performance status of Eastern Cooperative Oncology Group 0 and 1 showed prolonged OS (p<0.01). CONCLUSION: For recurrent AO/AOA after surgery followed by radiation therapy, TMZ could be recommended as a salvage therapy at the estimated efficacy equal to procarbazine, lomustine, and vincristine (PCV) chemotherapy at first relapse. For patients previously treated with PCV, TMZ is a favorable therapeutic option as 2nd line salvage chemotherapy with an acceptable toxicity rate.
Disease-Free Survival
;
Drug Therapy*
;
Follow-Up Studies
;
Humans
;
Lomustine
;
Oligodendroglioma*
;
Procarbazine
;
Recurrence
;
Retrospective Studies
;
Salvage Therapy
;
Vincristine